We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+12.82%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$13.3B
AUM Growth
+$1.51B
Cap. Flow
+$1.01B
Cap. Flow %
7.58%
Top 10 Hldgs %
83.56%
Holding
124
New
10
Increased
16
Reduced
22
Closed
5

Top Buys

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$1.09B
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$97.2M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$84.2M
4
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$54.3M
5
TCDA
Tricida, Inc. Common Stock
TCDA
+$44.7M

Top Sells

Rank Stock Value
1
AVXS
AveXis, Inc. Common Stock
AVXS
+$144M
2
ABLX
Ablynx NV
ABLX
+$119M
3
NKTR icon
Nektar Therapeutics
NKTR
+$29.3M
4
EXEL icon
Exelixis
EXEL
+$13.4M
5
PGNX
Progenics Pharmaceuticals Inc
PGNX
+$10.1M

Sector Composition

Rank Sector Weight
1 Healthcare 92.38%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FSTX
76
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$4.42M 0.03%
93,286
– –
APLS
77
DELISTED
Apellis Pharmaceuticals
APLS
$4.31M 0.03%
+196,078
New +$4.5M
NTRA icon
78
Natera
NTRA
$35.8B
$4.3M 0.03%
228,676
– –
ALKS icon
79
Alkermes
ALKS
$8.08B
$4.13M 0.03%
100,251
– –
AERI
80
DELISTED
Aerie Pharmaceuticals
AERI
$4.06M 0.03%
60,155
-155,500
-72% -$8.7M
FTSV
81
DELISTED
Forty Seven, Inc. Common Stock
FTSV
$4M 0.03%
+250,000
New +$3.88M
TTPH
82
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$3.34M 0.03%
46,750
– –
NBRV
83
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$3.27M 0.02%
3,753
– –
TNXP icon
84
Tonix Pharmaceuticals
TNXP
$154M
– –
0
– –
TRIL
85
DELISTED
Trillium Therapeutics Inc.
TRIL
$3.07M 0.02%
511,763
+102,440
+25% +$653K
KRYS icon
86
Krystal Biotech
KRYS
$10.6B
$2.97M 0.02%
200,000
– –
RIGL icon
87
Rigel Pharmaceuticals
RIGL
$712M
$2.95M 0.02%
104,161
-147,727
-59% -$5.26M
LUMO
88
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$2.42M 0.02%
56,364
– –
OVID icon
89
Ovid Therapeutics
OVID
$424M
$1.93M 0.01%
247,733
– –
RARX
90
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$1.77M 0.01%
177,952
– –
MDWD icon
91
MediWound
MDWD
$186M
$1.56M 0.01%
32,286
– –
RCUS icon
92
Arcus Biosciences
RCUS
$3.3B
$1.49M 0.01%
+121,534
New +$1.91M
CLLS
93
Cellectis
CLLS
$287M
$1.42M 0.01%
50,000
– –
TRVN
94
DELISTED
Trevena, Inc.
TRVN
$1.37M 0.01%
1,520
– –
ABUS icon
95
Arbutus Biopharma
ABUS
$845M
$1.32M 0.01%
180,582
– –
CRBP icon
96
Corbus Pharmaceuticals
CRBP
$166M
$1.25M 0.01%
8,248
-13,776
-63% -$2.5M
RNAC icon
97
Cartesian Therapeutics
RNAC
$215M
$1.24M 0.01%
3,125
– –
ADAP
98
DELISTED
Adaptimmune Therapeutics
ADAP
$1.19M 0.01%
100,000
– –
VIRX
99
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$1.18M 0.01%
15,905
– –
DVAX
100
DELISTED
Dynavax Technologies
DVAX
$1.14M 0.01%
75,000
– –
1 2 3
4
5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2018 Portfolio in Review

As of Q2 2018, Baker Bros. Advisors held 124 positions worth $13.3B, up 13% from $11.8B the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Baker Bros. Advisors deployed $1.01B of net new capital in Q2 2018, opening 10 new positions and adding to 16 existing holdings. Its largest new stake was Kiniksa Pharmaceuticals: 3,000,000 shares worth $52M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 94% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Exelixis, an estimated $13.4M trimmed.

  • Baker Bros. Advisors's largest Q2 2018 buy was Kiniksa Pharmaceuticals: 3,000,000 shares worth $52M.
  • Baker Bros. Advisors added most to BeOne Medicines Ltd in Q2 2018, an estimated $1.09B increase.
  • Baker Bros. Advisors's biggest Q2 2018 reduction was Exelixis, cutting an estimated $13.4M.
  • Baker Bros. Advisors fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $144M.
  • Baker Bros. Advisors's ten largest holdings make up 84% of its $13.3B portfolio in Q2 2018.
  • Baker Bros. Advisors opened 10 new positions and closed 5 in Q2 2018.
  • Baker Bros. Advisors's portfolio value rose 13% quarter-over-quarter to $13.3B.

Based on Baker Bros. Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.